Company Description
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally.
The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes.
In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software.
Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions.
It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies.
The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
| Country | United States |
| Founded | 1998 |
| IPO Date | Jul 17, 2014 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 650 |
| CEO | John Hanna |
Contact Details
Address: 8000 Marina Boulevard Brisbane, California 94005 United States | |
| Phone | 415 287 2300 |
| Website | caredx.com |
Stock Details
| Ticker Symbol | CDNA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001217234 |
| CUSIP Number | 14167L103 |
| ISIN Number | US14167L1035 |
| Employer ID | 94-3316839 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| John Walter Hanna Jr. | President, Chief Executive Officer and Director |
| Jeffrey A. Novack | General Counsel and Secretary |
| Jessica Meng | Chief Commercial Officer |
| Nathan A. Smith | Chief Financial Officer |
| Kashif Rathore | Chief Technology Officer |
| Dr. Robert N. Woodward Ph.D. | Chief Scientific Officer |
| Tina Jacobsen CFA | Vice President of Investor Relations |
| Natasha Moshirian Wagner | Vice President of Corporate Communications |
| Marica Grskovic Ph.D. | Chief Strategy Officer |
| Jing Huang Ph.D. | Chief Data and Artificial Intelligence Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 25, 2026 | 8-K/A | [Amend] Current report |
| Feb 25, 2026 | 10-K | Annual Report |
| Feb 24, 2026 | 8-K | Current Report |
| Feb 12, 2026 | SCHEDULE 13G/A | Filing |
| Feb 9, 2026 | SCHEDULE 13G | Filing |
| Feb 3, 2026 | 144 | Filing |
| Jan 15, 2026 | 144 | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Dec 18, 2025 | 8-K | Current Report |
| Dec 15, 2025 | 8-K | Current Report |